Clinical & Translational Oncology最新文献

{"title":"FXN predicts poor prognosis in colon adenocarcinoma and correlates with immune cell infiltration.","authors":"Mengya Sun, Qizhong Shi, Yonghui Mu, Chenglei Li, Wenchao Zhao, Na Han","doi":"10.1007/s12094-026-04361-1","DOIUrl":"10.1007/s12094-026-04361-1","url":null,"abstract":"<p><strong>Objective: </strong>Frataxin (FXN) is a mitochondrial protein involved in various cellular processes. To date, the role of FXN in the initiation and progression of colon adenocarcinoma (COAD) remains unclear. This study aimed to investigate FXN expression in COAD and its involvement in COAD initiation and progression.</p><p><strong>Methods: </strong>FXN expression in COAD was assessed via bioinformatics and immunohistochemistry (IHC) validation. The association between FXN expression and prognosis was evaluated using Kaplan‑Meier analysis and Cox regression analysis. Gene Ontology-Biological Process (GO-BP) enrichment analysis was performed to explore the potential biological functions of FXN in COAD. Functional assays (CCK-8, colony formation, Transwell) were used to confirm the critical role of FXN in COAD cell proliferation, migration, and invasion. R language, single‑sample gene-based enrichment analysis (ssGSEA), and correlation analysis were applied to identify associations between FXN expression and immune infiltration, immunotherapy response, and drug sensitivity.</p><p><strong>Results: </strong>Compared with normal colon tissue, FXN expression was upregulated in COAD tissue (p < 0.05), and high FXN expression predicted poor prognosis in COAD patients (p < 0.05). GO-BP enrichment analysis revealed that FXN correlated with cell proliferation and microtubule dynamics (p < 0.05). Downregulating FXN inhibited proliferation, migration, and invasion of COAD cells (p < 0.05). FXN expression showed a correlation with several immune cells and immune cell markers, but no significant correlation with immunophenoscore (IPS). Drug sensitivity analysis indicated that FXN was associated with COAD samples' sensitivity to several anticancer drugs (p < 0.001).</p><p><strong>Conclusions: </strong>FXN may promote the malignant phenotype of COAD and correlate with immune infiltration, serving as a prognostic biomarker and a potential reference for chemotherapy but not for immune checkpoint blockade.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4806-4818"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13601114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147965285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ovarian tissue cryopreservation in girls and adolescents at risk of gonadotoxicity: a 15-year experience in 159 patients from a referral program.","authors":"Mara Andrés Moreno, Javier Gómez Chacón, Patricia Torres Gómez, Pedro José Fernández Colom, Jorge Cortés Sáez, Alfredo Marco Macián, Helena Martínez Sánchez, Bárbara Torres Guerola, Teresa Tormo Alcañiz, Pilar Morillas Amat, Patrocinio Polo Sánchez, José María Rubio Rubio, Edurne Novella-Maestre, Vicente Mirabet Lis, Adela Cañete Nieto, Francisca Moreno Macián","doi":"10.1007/s12094-026-04351-3","DOIUrl":"10.1007/s12094-026-04351-3","url":null,"abstract":"<p><strong>Purpose: </strong>To report a 15-year single-center experience of a pediatric fertility preservation program based on ovarian tissue cryopreservation (OTC), focusing on patient selection, program logistics, and endocrine and reproductive outcomes with explicit consideration of age- and treatment-related evaluability.</p><p><strong>Methods/patients: </strong>Retrospective observational study including all girls and adolescents who underwent OTC between 2010 and 2025. Eligibility was based on structured gonadotoxic risk assessment integrating diagnosis, alkylating-agent exposure, radiotherapy fields/doses, and hematopoietic stem cell transplantation (HSCT). Outcomes were analyzed descriptively. Ovarian function was assessed in patients considered evaluable at last follow-up (aged ≥ 13 years, off treatment, and with endocrine follow-up available).</p><p><strong>Results: </strong>A total of 159 patients underwent OTC (median age at OTC 11.0 years). Malignant diseases accounted for 131/159 (82.3%), including leukemias/lymphoblastic lymphomas 35/159 (22.0%) managed in the context of HSCT, and other malignancies 96/159 (60.4%); non-malignant conditions accounted for 28/159 (17.7%). OTC was coordinated with another procedure under anesthesia in 106/159 (66.6%), and ovarian transposition was performed in 27/159 (17.0%) when abdominal and/or pelvic radiotherapy represented the main gonadotoxic risk. Among patients evaluable for ovarian function (n = 83), primary ovarian insufficiency was diagnosed in 36/83 (43.4%) (36/159, 22.6% overall); hormone replacement therapy was administered in 31/36 (86.1%).</p><p><strong>Conclusion: </strong>A structured, risk-based OTC program can be integrated into pediatric oncology care with close logistical coordination. Clear definition of evaluability denominators and long-term multidisciplinary follow-up are essential for accurate interpretation of endocrine outcomes in this high-risk population.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4695-4705"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147700076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid biopsy in modern medicine: advancing diagnostics from molecular insights to clinical practice.","authors":"Vivek Kumar Dhiman, Stuti Srivastava, Manju Kumari, Devendra Singh","doi":"10.1007/s12094-026-04363-z","DOIUrl":"10.1007/s12094-026-04363-z","url":null,"abstract":"<p><p>Liquid biopsy is the analysis of tumour components in bodily fluids and is increasingly considered a complementary approach to conventional diagnostics. Although tissue biopsy is the gold standard in clinical diagnostics, this approach is invasive, spatially restricted, and often difficult to perform repeatedly. Liquid biopsy is a minimally invasive approach for molecular analysis of tumours using circulating tumour DNA, cells, and extracellular vesicles, including exosomes. Although significant progress in this field has been made, a comprehensive synthesis of the biological basis, analytical methods, and clinical utility of these circulating markers still seems fragmented, with considerable methodological heterogeneity hindering standardised clinical use. This, in turn, underscores the need to understand the appropriate approach to the clinical utility of liquid biopsy. This review article is a concise and comprehensive synthesis of important liquid biopsy markers, a review of detection methods and their utility in cancer management, and an examination of the methodological limitations of this approach, including sensitivity, standardisation, and interpretation. This review article consolidates current evidence and highlights the importance of liquid biopsy and its utility for disease monitoring and precision oncology-based therapeutic decisions.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4469-4490"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147718885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune phenotype and RAS/BRAF status predict outcomes after lung metastasectomy for colorectal cancer.","authors":"Berta Martin-Cullell, Aida Piedra, Anna Cristina Virgili, Caterina Fumagalli, Paula Cerdà, Oriol Mirallas, Judit Sanz, Sara Restrepo, Juan Carlos Trujillo, Elisabeth Martínez, Jose Belda-Sanchís, Justyna Szafranska, David Páez","doi":"10.1007/s12094-026-04344-2","DOIUrl":"10.1007/s12094-026-04344-2","url":null,"abstract":"<p><strong>Purpose: </strong>Colorectal cancer (CRC) presents a marked biological heterogeneity, and the lung is a frequent site of metastatic spread. Although pulmonary metastasectomy can lead to a long-term survival, recurrence rates remain high and prognostic markers are lacking. This study evaluated the prognostic value of clinical, molecular, and histopathological features in CRC patients undergoing lung metastasectomy.</p><p><strong>Methods: </strong>A retrospective cohort of CRC patients who underwent pulmonary metastasectomy at Hospital de la Santa Creu i Sant Pau between September 2011 and October 2023 was analyzed. Clinical variables, molecular alterations, and histopathological characteristics were collected. Immune phenotype (IP) and histological growth pattern (HGP) were assessed by pathologists and survival outcomes were estimated using Kaplan-Meier methods.</p><p><strong>Results: </strong>61 patients (median age 67 years) were included. Median overall survival (OS) was 73.1 months, and median recurrence-free survival (RFS) was 17.5 months. Early-stage CRC at diagnosis (stages I-II) was associated with longer RFS (42.7 vs 12.6 months; p = 0.02), whereas elevated preoperative CEA levels predicted shorter RFS (7.1 vs. 21.3 months, p = 0.005) and lung-only metastatic disease was associated with longer OS (80.3 vs 28.6 months; p = 0.01). An immune-desert IP correlated with shorter RFS (4.0 vs. 20.4 months, p = 0.03), and tumors harboring RAS/BRAF mutations had worse lung-specific RFS (14.9 vs. 24.3 months, p = 0.034).</p><p><strong>Conclusions: </strong>An immune-desert phenotype and RAS/BRAF mutations identify CRC patients at higher risk of recurrence after lung metastasectomy, whereas earlier CRC stage and solitary lung metastasis are associated with more favorable outcomes. Integrating clinical, molecular, and immune-histologic features may improve selection for pulmonary metastasectomy in oligometastatic CRC.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4758-4766"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robotic vs. laparoscopic rectal cancer surgery in high BMI patients: a systematic review and meta-analysis.","authors":"Chengzheng Wang, Huaicheng Zhou","doi":"10.1007/s12094-026-04394-6","DOIUrl":"10.1007/s12094-026-04394-6","url":null,"abstract":"<p><strong>Objective: </strong>To compare the perioperative outcomes, postoperative complications, and oncologic results between robotic-assisted and laparoscopic rectal cancer surgeries in patients with high BMI.</p><p><strong>Methods: </strong>A meta-analysis was conducted under the PRISMA guidelines. PubMed, SCOPUS, Embase, and Cochrane Library databases were searched from inception to May 2025 for studies comparing robotic and laparoscopic rectal cancer surgeries among patients with BMI ≥ 28 kg/m². Five studies included data for 700 cases in the robotic group (RG) and 2102 cases in the laparoscopic group (LG). The main areas of outcome investigations included operative time, length of hospital stay (LOHS), conversion rates, overall postoperative complications, and harvested lymph nodes. Pooled estimates were analyzed using the random-effect models.</p><p><strong>Results: </strong>The pooled analysis of five studies showed that the robotic group had a significantly shorter hospital stay and a lower conversion rate than the laparoscopic group (P < 0.05), while operative time was approximately 30 min shorter in the laparoscopic group (P < 0.05). Following exclusion of Zhao 2024, subanalysis of the remaining four studies demonstrated that the laparoscopic group still had a significantly shorter operative time and the robotic group maintained a significantly lower conversion rate; however, a significant difference in hospital stay was no longer present, and no significant differences were found for harvested lymph nodes or postoperative complications. No major difference was observed concerning lymph node yield and readmission rates between the surgical measures.</p><p><strong>Conclusion: </strong>Robotic surgery was associated with a significantly lower conversion rate, whereas laparoscopic surgery was associated with significantly shorter operative times; no consistent advantage was observed for hospital stay, as this finding was not replicated in sensitivity analysis. Further high-quality studies are warranted to confirm these results.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4819-4831"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147976919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modulation of HMGB1, PRF1, TRAIL, and M-CSF after TARGIT-IORT in breast-conserving surgery: defining a unique acute immune landscape.","authors":"Yastira Ramdas, Catherine Worsley, Pieter Willem Meyer, Carol-Ann Benn","doi":"10.1007/s12094-026-04353-1","DOIUrl":"10.1007/s12094-026-04353-1","url":null,"abstract":"<p><strong>Background: </strong>Targeted intraoperative radiotherapy (TARGIT-IORT) delivers a single high-dose boost to the tumor bed during breast-conserving surgery (BCS) and is now recommended only within clinical trials or registries. Its acute systemic immunogenic effects relative to BCS-only are not well characterized.</p><p><strong>Methods: </strong>Women with histologically confirmed breast carcinoma were allocated in an alternating 1:1 sequence to BCS + TARGIT-IORT or BCS-only groups. Peripheral blood was sampled pre-operatively and 24 h post-surgery. ICD and cytokine/DAMP mediators, including HMGB1, PRF1, TRAIL, FASL-NFSF6, CASP-8, GZMB, CRT, TLR4, RAGE, GDF15, and M-CSF, were quantified using ELISA. Perioperative changes were analyzed using the Wilcoxon signed-rank test; between-group Δ differences were assessed using the Mann-Whitney U test.</p><p><strong>Results: </strong>Forty-two patients were enrolled (26 BCS + TARGIT-IORT; 16 BCS-only). TARGIT-IORT induced a distinct early immune shift across ICD markers. HMGB1 showed the most pronounced change (3410.5 → 359.8 pg/ml; p < 0.001), significantly greater than that after BCS-only (1040.7 → 263.6 pg/ml; Δp < 0.001). TRAIL (246.1 → 155.5 pg/ml; p = 0.001) and FASL-NFSF6 (1087.1 → 839.3 pg/ml; p = 0.003) also declined significantly after TARGIT-IORT, whereas changes following BCS alone were modest. TARGIT-IORT increased M-CSF (266.7 → 386.7 pg/ml; p = 0.037) and reduced TLR4 (1456.3 → 1331.3 ng/ml; p = 0.007), with no significant perioperative changes in RAGE, GDF15, CRT, GZMB, or CASP-8.</p><p><strong>Discussion: </strong>Within 24 h, TARGIT-IORT generates a coordinated ICD-related and cytokine/DAMP signature, marked HMGB1 depletion, death ligand modulation, TLR4 engagement, and M-CSF upregulation, consistent with rapid immune priming. These findings are exploratory and should be interpreted within a translational framework. Larger, randomized multicentre studies with extended longitudinal and tissue-level immune profiling are needed to confirm these signals.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4666-4682"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13601154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147718911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mastitis as a risk factor for breast cancer: a systematic review and meta-analysis.","authors":"Aryane Cristina de Figueiredo Azevedo, Raissa Martins da Silva, Felipe Alves de Paiva, Luis Henrique Rios Moreira Rego, Francisco Cezar Aquino de Moraes","doi":"10.1007/s12094-026-04303-x","DOIUrl":"10.1007/s12094-026-04303-x","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is the most common cancer among women worldwide, accounting for more than 2.3 million new cases annually. Although chronic inflammation is a well-established risk factor for cancer, the association between mastitis and BC has not yet been clearly established. Therefore, this study aims to investigate mastitis as a potential risk factor for BC.</p><p><strong>Methods: </strong>We performed a random-effects meta-analysis to estimate the odds ratio (OR) and hazard ratio (HR). P values lower than 0.05 were considered statistically significant, with 95% confidence intervals (CI). Statistical analyses were conducted using R Studio software version 4.4.2, considering P < 0.05 as statistically significant.</p><p><strong>Results: </strong>Our meta-analysis included 54,216 patients, of whom 18,753 (34.6%) had mastitis, while 35,463 (65.4%) comprised the control group. Our results support that the risk of BC is higher among patients with a history of mastitis (OR: 2.12; 95% CI: 1.44-3.11; p = 0.0423). Similarly, longitudinal analysis based on total follow-up also confirmed an increased risk of BC in the mastitis group (HR: 2.0057; 95% CI: 1.1739-3.4269; p = 0.011).</p><p><strong>Conclusion: </strong>This meta-analysis highlights a possible association between the presence of mastitis and BC, substantially contributing to the advancement of understanding regarding risk factors for this cancer. Prospective studies using robust detection methods and paired tissue analyses are needed to confirm these findings and clarify the role of mastitis in breast tumorigenesis.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4657-4665"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13601124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147662854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An automated, workload-adjusted framework for continuous quality assessment in clinical radiation oncology.","authors":"Jose López Torrecilla, Pilar Ma Samper Ots, Germán Juan Rijo, Pilar Rey Castro, Jose Bayón Llera, Carlos Jose Ferrer Albiach","doi":"10.1007/s12094-026-04366-w","DOIUrl":"10.1007/s12094-026-04366-w","url":null,"abstract":"<p><strong>Background: </strong>Quality assessment in radiation oncology is essential to ensure safe, timely, and effective care. Although multiple quality indicators have been proposed, their routine implementation is often limited by heterogeneous definitions, manual data collection, and the lack of adjustment for clinical workload and treatment complexity.</p><p><strong>Methods: </strong>Within a national quality initiative, a structured revision of previously proposed quality indicators was performed. A survey among heads of Radiation Oncology departments was conducted to assess the relevance, feasibility, and management value of existing indicators. Based on survey results, a reduced set of prioritized indicators was selected and operationally defined for automated extraction from routine radiotherapy information systems. In parallel, a workload-based complexity stratification was developed, defining six levels for external beam radiotherapy and five levels for brachytherapy. Automated data extraction was implemented using commonly deployed clinical information systems, enabling continuous indicator monitoring without additional manual data entry.</p><p><strong>Results: </strong>Forty-one department heads participated in the survey, with strong support for reinforcing quality indicator use. The original set of 29 indicators was reduced to 17 prioritized indicators covering structure, process, and outcome domains. Process indicators related to treatment preparation times for conventional and special techniques showed the highest acceptance. Automated extraction resulted in a standardized quality report enabling routine monitoring of indicator performance and data quality. The workload-based complexity stratification revealed substantial heterogeneity across treatment techniques and enabled contextual interpretation of activity and performance.</p><p><strong>Conclusions: </strong>This study presents an automated and workload-adjusted framework for continuous quality assessment in Radiation Oncology. By integrating prioritized quality indicators, workload-based complexity stratification, and automated data extraction, the proposed approach supports sustainable quality monitoring and facilitates meaningful inter-center comparison. Although developed within a national initiative, the methodological principles are broadly applicable to other healthcare systems and technologically complex oncological settings.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4937-4946"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147823167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of borderline resectable NSCLC: a narrative review.","authors":"Xabier Mielgo-Rubio, Samantha Aso González, Eider Azkona Uribelarrea, Sergio Bolufer Nadal, Virginia Calvo De Juan, Margarita Martín Martín, Arturo Navarro-Martín, Rafael López Castro, Mariano Provencio Pulla, Juan Carlos Trujillo Reyes, Felipe Couñago","doi":"10.1007/s12094-026-04305-9","DOIUrl":"10.1007/s12094-026-04305-9","url":null,"abstract":"<p><p>Borderline resectable NSCLC (BR-NSCLC) represents a complex clinical entity in which surgical resection is technically feasible but oncological benefit and margin negativity are uncertain. Advances in multimodal therapies, particularly the incorporation of neoadjuvant and/or perioperative chemo-immunotherapy (CT-IO), are redefining the management of these patients, as this strategy has significantly increased complete and major pathological response rates, nodal downstaging and survival. However, challenges remain, including standardized criteria for defining resectability, optimal therapeutic strategies, the role of extending lung resection after neoadjuvant CT-IO, therapeutic options in patients who do not undergo resection after neoadjuvant CT-IO, optimal treatment in patients with actionable genomic alterations, and the search for biomarkers to guide decision making. This narrative review summarizes the evolving definitions of resectability, analyses evidence supporting neoadjuvant and perioperative immunotherapy in BR-NSCLC and explores current strategies to convert initially unresectable tumours to resectable, from a multidisciplinary approach, which is crucial in this rapidly changing landscape. Given the lack of universally standardized 'borderline resectable' criteria, we propose a pragmatic operational framework that explicitly separates resectability (probability of achieving an R0 resection with meaningful oncologic benefit) from operability (physiologic ability to tolerate the planned extent of resection). We also provide a multidisciplinary treatment pathway to support consistent decision-making across common clinical scenarios.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4277-4296"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147678408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is radiotherapy still an option for residual retroperitoneal masses in stage IIC seminoma?","authors":"Halil Cumhur Yıldırım, Şahin Dikmen, Yeliz Gürsoy, Nuri Kaydıhan, Fazilet Öner Dinçbaş","doi":"10.1007/s12094-026-04362-0","DOIUrl":"10.1007/s12094-026-04362-0","url":null,"abstract":"<p><strong>Purpose: </strong>In patients with clinical stage IIC seminoma, residual retroperitoneal masses are detected in up to 80% of patients after chemotherapy. Lesions < 3 cm are generally monitored; however, the management of patients with residuals > 3 cm remains a matter of debate. Herein, we present a case series of these patients who underwent radiotherapy (RT) and discuss the role of RT in these cases.</p><p><strong>Methods: </strong>Three patients with de novo and two patients with relapsed stage IIC seminoma who underwent RT for retroperitoneal residual masses after chemotherapy at two centers between 2014 and 2025 were retrospectively evaluated. All treatment decisions were made by a multidisciplinary board.</p><p><strong>Results: </strong>The median age of the patients was 43 (26-47) years, and the median follow-up was 30 (10-120) months. Following radical orchiectomy, all patients received 3-4 cycles of BEP chemotherapy. The median size of the post-chemotherapy residual was 6.5 (3.2-8.5) cm. PET-CT was positive with SUVmax > 3 for all patients. Two patients received only paraaortic RT, three patients received paraaortic + ipsilateral pelvic lymph node RT with a total dose of 25.5 Gy. An additional dose of 10 Gy was prescribed to the residual mass. All treatments were implemented with intensity-modulated radiotherapy (IMRT). Three patients experienced grade 1 nausea. No recurrence or secondary malignancy was detected at final follow-up.</p><p><strong>Conclusion: </strong>Radiotherapy may be considered as a potential non-invasive option for managing residual retroperitoneal masses after chemotherapy in stage IIC seminoma, particularly in patients with a high risk of recurrence and in whom retroperitoneal lymph node dissection (RPLND) is anticipated to be associated with morbidity.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"4832-4838"},"PeriodicalIF":2.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147787938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}